Prevention and Treatment of Human Papillomavirus in Men Benefits Both Men and Women

Overview

Journal Front Cell Infect Microbiol

Specialties Cell Biology
Infectious Diseases
Microbiology

Date 2022 Dec 12

PMID 36506029

Authors

Kangni Zou

Yue Huang

Zhengyu Li

Affiliations

Soon will be listed here.

Abstract

Men should not be overlooked in research on human papillomavirus (HPV) and its associated genital diseases. This is because men infected with HPV are not only at higher risk of genital cancers, but also increase their partners' risk of HPV infection and reinfection through sexual contact. Herein, we summarized the state of knowledge regarding the prevention and treatment of HPV infection in men as well as the possible effects of the prevention and treatment of HPV in men on their female partners. Condom use, smoking cessation, male circumcision, and HPV vaccination for men each play an important role in preventing HPV infection within heterosexual couples. Additionally, men could choose to test for certain types of HPV, such as the oncogenic HPV16 or HPV18 strains, as part of a routine screening program when their partner is positive for HPV. Although there is no recognized treatment for HPV infection as of yet, immunotherapy drugs, such as toll-like receptor agonists, therapeutic HPV vaccines, and immune checkpoint inhibitors, have shown promising results in clinical trials and in actual clinical practice. HPV infection in men also increases the risk of cervical cancer in their female partners. Because of the high partner concordance for HPV demonstrated in prior research, the prevention and treatment of HPV in men should be explored more comprehensively in future research.

Citing Articles

A review of the carcinogenic potential of human papillomavirus (HPV) in urological cancers.

Zolfi E, Khaleghi Mehr F, Emtiazi N, Moradi Y Virol J. 2025; 22(1):53.

PMID: 40022189 PMC: 11871667. DOI: 10.1186/s12985-025-02682-1.

Human Papillomavirus Infection in Partners of Women Attending Cervical Cancer Screening: A Pilot Study on Prevalence, Distribution, and Potential Use of Vaccines.

Sucato A, Serra N, Butta M, Gregorio L, Pistoia D, Capra G Vaccines (Basel). 2025; 13(2).

PMID: 40006719 PMC: 11861694. DOI: 10.3390/vaccines13020172.

Prevalence of Human Papillomavirus and Genotype Distribution in Chinese Men: A Systematic Review and Meta-Analysis.

Li Y, Zhao F, Wu D, Qin C, Lu Y, Yang Y Cancer Med. 2025; 14(4):e70686.

PMID: 39960180 PMC: 11831462. DOI: 10.1002/cam4.70686.

Breaking barriers: why including boys and men is key to HPV prevention.

Naidoo D, Govender K, Mantell J BMC Med. 2024; 22(1):525.

PMID: 39516809 PMC: 11549739. DOI: 10.1186/s12916-024-03701-8.

A review of urinary HPV testing for cervical cancer management and HPV vaccine surveillance: rationale, strategies, and limitations.

Cheng L, Wang R, Yan J Eur J Clin Microbiol Infect Dis. 2024; 43(12):2247-2258.

PMID: 39400675 DOI: 10.1007/s10096-024-04963-z.

References

Arbyn M, de Sanjose S, Saraiya M, Sideri M, Palefsky J, Lacey C . EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer. 2012; 131(9):1969-82. PMC: 3429628. DOI: 10.1002/ijc.27650. View

Mifsud E, Tan A, Jackson D . TLR Agonists as Modulators of the Innate Immune Response and Their Potential as Agents Against Infectious Disease. Front Immunol. 2014; 5:79. PMC: 3939722. DOI: 10.3389/fimmu.2014.00079. View

Chandra J, Woo W, Finlayson N, Liu H, McGrath M, Ladwa R . A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC). Cancer Immunol Immunother. 2020; 70(3):743-753. PMC: 10991317. DOI: 10.1007/s00262-020-02720-7. View

Lehtinen M, Soderlund-Strand A, Vanska S, Luostarinen T, Eriksson T, Natunen K . Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I). Int J Cancer. 2017; 142(5):949-958. DOI: 10.1002/ijc.31119. View

Svare E, Kjaer S, Worm A, Osterlind A, Meijer C, van den Brule A . Risk factors for genital HPV DNA in men resemble those found in women: a study of male attendees at a Danish STD clinic. Sex Transm Infect. 2002; 78(3):215-8. PMC: 1744457. DOI: 10.1136/sti.78.3.215. View

Lu B, Wu Y, Nielson C, Flores R, Abrahamsen M, Papenfuss M . Factors associated with acquisition and clearance of human papillomavirus infection in a cohort of US men: a prospective study. J Infect Dis. 2009; 199(3):362-71. DOI: 10.1086/596050. View

Nicolau S, Camargo C, Stavale J, Castelo A, Dores G, Lorincz A . Human papillomavirus DNA detection in male sexual partners of women with genital human papillomavirus infection. Urology. 2005; 65(2):251-5. DOI: 10.1016/j.urology.2004.09.031. View

Bruni L, Saura-Lazaro A, Montoliu A, Brotons M, Alemany L, Diallo M . HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019. Prev Med. 2021; 144:106399. DOI: 10.1016/j.ypmed.2020.106399. View

Malagon T, MacCosham A, Burchell A, El-Zein M, Tellier P, Coutlee F . Sex- and Type-specific Genital Human Papillomavirus Transmission Rates Between Heterosexual Partners: A Bayesian Reanalysis of the HITCH Cohort. Epidemiology. 2021; 32(3):368-377. PMC: 8012224. DOI: 10.1097/EDE.0000000000001324. View

10.

Grandahl M, Neveus T . Barriers towards HPV Vaccinations for Boys and Young Men: A Narrative Review. Viruses. 2021; 13(8). PMC: 8402923. DOI: 10.3390/v13081644. View

11.

Lehtinen M, Baussano I, Paavonen J, Vanska S, Dillner J . Eradication of human papillomavirus and elimination of HPV-related diseases - scientific basis for global public health policies. Expert Rev Vaccines. 2019; 18(2):153-160. DOI: 10.1080/14760584.2019.1568876. View

12.

Pal A, Kundu R . Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy. Front Microbiol. 2020; 10:3116. PMC: 6985034. DOI: 10.3389/fmicb.2019.03116. View

13.

Schmeler K, Sturgis E . Expanding the benefits of HPV vaccination to boys and men. Lancet. 2016; 387(10030):1798-9. DOI: 10.1016/S0140-6736(16)30314-2. View

14.

Schroeder T, Sengelmann R . Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream. J Am Acad Dermatol. 2002; 46(4):545-8. DOI: 10.1067/mjd.2002.120444. View

15.

Smith J, Backes D, Hudgens M, Mei W, Chakraborty H, Rohner E . Male Circumcision Reduces Penile HPV Incidence and Persistence: A Randomized Controlled Trial in Kenya. Cancer Epidemiol Biomarkers Prev. 2021; 30(6):1139-1148. PMC: 8172477. DOI: 10.1158/1055-9965.EPI-20-1272. View

16.

Schabath M, Villa L, Lazcano-Ponce E, Salmeron J, Quiterio M, Giuliano A . Smoking and human papillomavirus (HPV) infection in the HPV in Men (HIM) study. Cancer Epidemiol Biomarkers Prev. 2011; 21(1):102-10. PMC: 3253903. DOI: 10.1158/1055-9965.EPI-11-0591. View

17.

Skoulakis A, Fountas S, Mantzana-Peteinelli M, Pantelidi K, Petinaki E . Prevalence of human papillomavirus and subtype distribution in male partners of women with cervical intraepithelial neoplasia (CIN): a systematic review. BMC Infect Dis. 2019; 19(1):192. PMC: 6390310. DOI: 10.1186/s12879-019-3805-x. View

18.

Skegg D, Corwin P, Paul C, DOLL R . Importance of the male factor in cancer of the cervix. Lancet. 1982; 2(8298):581-3. DOI: 10.1016/s0140-6736(82)90661-4. View

19.

Garbuglia A, Lapa D, Sias C, Capobianchi M, Del Porto P . The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease. Front Immunol. 2020; 11:188. PMC: 7040023. DOI: 10.3389/fimmu.2020.00188. View

20.

Owen A, Fults J, Patil N, Hernandez A, Bohannon J . TLR Agonists as Mediators of Trained Immunity: Mechanistic Insight and Immunotherapeutic Potential to Combat Infection. Front Immunol. 2021; 11:622614. PMC: 7930332. DOI: 10.3389/fimmu.2020.622614. View